Switch

DRUG4 trials

Sponsors

Veterans Medical Research Foundation, Niklaus Labhardt, University of Colorado, Denver, Dartmouth-Hitchcock Medical Center

Conditions

Adjuvant TreatmentBreast CancerEarly Stage Breast CancerHIV-1-infectionHIV/AIDSInsulin ResistanceMetabolic Syndrome XSchizophrenia

Phase 2

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

RecruitingNCT07071038

Dartmouth-Hitchcock Medical CenterAdjuvant Treatment, Breast Cancer, Early Stage Breast Cancer

Start: 2025-10-17End: 2027-08-05Target: 62Updated: 2026-02-12

Phase 4

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

CompletedNCT00338949

Veterans Medical Research FoundationInsulin Resistance, Metabolic Syndrome X, Schizophrenia

Start: 2006-06-30End: 2009-12-31Updated: 2020-10-30

Unknown Phase

Switch Either Near Suppression Or THOusand

CompletedNCT03088241

Niklaus LabhardtHIV/AIDS

Start: 2017-08-01End: 2020-05-23Updated: 2022-03-22

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

CompletedNCT04301661

University of Colorado, DenverHIV-1-infection

Start: 2020-03-06End: 2021-12-17Updated: 2023-01-09

Related Papers

Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial

Journal of Antimicrobial Chemotherapy2021-01-1916 citations

Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho

PLoS Medicine2020-09-1624 citations

SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.

2018-02-125 citations